Abstract
We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.
MeSH terms
-
Bone Marrow Transplantation / adverse effects
-
Cell Survival
-
Epstein-Barr Virus Infections / immunology
-
Epstein-Barr Virus Infections / pathology
-
Epstein-Barr Virus Infections / therapy*
-
Epstein-Barr Virus Infections / virology
-
Genetic Markers
-
Genetic Vectors / analysis
-
Herpesvirus 4, Human / immunology*
-
Humans
-
Immunotherapy, Adoptive*
-
Lymphoproliferative Disorders / etiology
-
Lymphoproliferative Disorders / immunology
-
Lymphoproliferative Disorders / prevention & control*
-
Lymphoproliferative Disorders / therapy
-
Lymphoproliferative Disorders / virology
-
T-Lymphocytes, Cytotoxic / immunology*
-
T-Lymphocytes, Cytotoxic / transplantation
-
Time Factors
-
Treatment Outcome